NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

REal World MAIA UK OutcomEs

Not Yet RecruitingN/A

Sponsor: The Royal Wolverhampton Hospitals NHS Trust

Conditions: Myeloma

Countries: United Kingdom

This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥18 years
* Diagnosis of NDMM
* Not eligible for autologous stem cell transplant at diagnosis
* Received frontline DRd treatment following NICE approval (post-September 2023)
* Minimum 3 months of follow-up data available

Exclusion Criteria:

* Participation in an interventional clinical trial for first-line therapy
* Insufficient treatment or follow-up data for analysis
* DRd used in relapsed/refractory setting rather than newly diagnosed disease

Locations (1)

Wolverhampton, United Kingdom